Exhibit 99.2

Nasdaq: VANI www.vivani.com March 2024

Disclaimers The following slides and any accompanying oral presentation contain forward - looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the "s afe harbor" created by those sections. All statements in this release that are not based on historical fact are "forward looking statements." These sta tements may be identified by words such as "estimates," "anticipates," "projects," "plans" or "planned," "strategy," “goal," "seeks," "may," "will," "expe cts ," "intends," "believes," "should," and similar expressions, or the negative versions thereof, and which also may be identified by their context. All statements that ad dress operating performance or events or developments that Vivani Medical, Inc. ("Vivani", the "Company", "we" or "us) expects or anticipates will occur in the future, such as stated objectives or goals, our products and their therapeutic potential and planned development, the indications that we intend to target, our te chnology, our business and strategy, milestones, addressable markets, or that are not otherwise historical facts, are forward - looking statements. While man agement has based any forward - looking statements included in this presentation on its current expectations, the information on which such expectations were based may change. Forward - looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from t hose in the forward - looking statements as a result of various factors. These risks and uncertainties include, but are not limited to, that we may fail to complete any required pre - clinical activities for NPM - 115. NPM - 119 or otherwise commence our planned clinical trials for these products under development; conduct any pre - clinical activities of our other products; our products may not demonstrate safety or efficacy in clinical trials; we may fail to secure marketing a ppr ovals for our products; there may be delays in regulatory approval or changes in regulatory framework that are out of our control; our estimation of addressable markets of our products may be inaccurate; we may fail to timely raise additional required funding; more efficient competitors or more effective competing t rea tment may emerge; we may be involved in disputes surrounding the use of our intellectual property crucial to our success; we may not be able to attract a nd retain key employees and qualified personnel; earlier study results may not be predictive of later stage study outcomes; and we are dependent on third - pa rties for some or all aspects of our product manufacturing, research and preclinical and clinical testing. Additional risks and uncertainties are described in ou r Annual Report on Form 10 - K filed on March 31, 2023, and our subsequent filings with the SEC. We urge you to consider those risks and uncertainties in ev alu ating our forward - looking statements. We caution readers not to place undue reliance upon any such forward - looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any fo rward - looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto, or any change in eve nts , conditions, or circumstances on which any such statement is based. Certain information contained in this presentation relates to or is based on studies, publications, surveys and other data obtained from third party sources and the Company’s own internal estimates and research. While we believe these third - party sources to be reliable as of the date of this presentation, we have not independently verified, and make no representation as to the adequacy, fairness, a ccu racy or completeness of, any information obtained from third - party sources. Finally, while we believe our own internal research is reliable, such research ha s not been verified by any independent source. All of our therapies are still investigational and have not been approved by any regulatory authority for an y use. 2

Vivani Executive Leadership Team • Co - founder/Co - inventor of Vivani technology • PhD Bioengineering (UCSF/UC Berkeley) • Management of Technology Certificate at Haas School of Business • Research focused on diabetes treatment • Formerly at Boston Scientific and Minimed Adam Mendelsohn PhD – CEO/Director • Numerous COO and Executive Positions at Device and Drug - Device Companies, including: • CTO at Dance Biopharm, COO at Avid Bio • Exec VP at Prima Biomed, Sr. VP at Nektar Therapeutics (responsible for Exubera approval), and Worldwide VP at Johnson & Johnson Truc Le, MBA – Chief Operations Officer • Former Chief Medical Officer for Eiger BioPharmaceuticals and Dance BioPharm • Former VP of Medical Development for Amylin • Former Director at GSK, Global Head of Clinical Strategy for Avandia • Former Board member of ViaCyte , Inc. Lisa Porter, MD – Chief Medical Officer • Former Sr. VP and CFO Miramar Labs • Former Sr. VP and CFO AGA Medical • Former CFO Nektar Therapeutics, OraVax and Haemonetics • Current Board director: Quantum - Si and Elutia , Inc. • Involved in/Directed 2 IPOs, 2 reverse mergers and 1 SPAC Brigid A. Makes, MBA – Chief Financial Officer • Former Executive Director at AstraZeneca with leadership roles in regulatory affairs, drug development, commercial and business development • Former Vivani Board observer for AZ • Former PhaseBio Board observer for AZ (prior to IPO) • Former Director at Cephalon and Rhone Poulenc Rorer Donald Dwyer, MBA – Chief Business Officer 3

Vivani Medical, Inc. 4 Lead programs NPM - 115 and NPM - 119 are miniature, six - month, GLP - 1 (exenatide) implants under development for the treatment of chronic weight management in obese or overweight patients and type 2 diabetes, respectively. NPM - 139 (semaglutide implant) is also under development for chronic weight management with the added potential benefit of once - yearly administration. An innovative, biopharmaceutical company developing a portfolio of miniature, long - term, drug implants to treat chronic diseases. Our NanoPortal ™ platform technology enables the design of implants aimed at improving medication non - adherence and tolerability. Vivani is well - positioned to advance NPM - 115 and NPM - 119 towards potentially transformational milestones in 2024.

Feline Pre - Diabetes & Diabetes >$0.5B Human Obesity >$50B 5 Company Pipeline If Approved, Vivani Products will Compete in Markets with Large Potential Indication Feasibility Pre - Clinical Clinical Market Size* Human Type II Diabetes Human Obesity NPM - 119 exenatide >$20B >$50B NPM - 139 Vivani * Estimated Market Sizes where Vivani products would compete, if approved. Does not represent future sales or revenue estimat es of Vivani pipeline products JP Morgan analyst Richard Vosser estimates GLP - 1 Market reaches $71 billion by 2032 (9/11/2023). We assume >$20B for type 2 diabetes and >$50B for chronic weight management in obese or overweight patients ** In Partnership with Okava Pharmaceuticals, Inc. OKV - 119** exenatide NPM - 115 h igh - dose exenatide semaglutide

Drug Implants Proprietary Platform Technology

Potential application with many molecular types Designed to assure adherence Minimally - fluctuating and tunable delivery profiles NanoPortal TM : Innovative Delivery Technology Drug Reservoir Nanotube Membrane 7

By precisely adjusting nanotubes to molecule size, interactions between drug and nanotube walls can result in desirable release profiles over time, including near constant release NanoPortal TM : How it Works... Pore too small: No release Pore target size: Near constant release 8 Pore too large: Burst release

Near - constant and minimally - fluctuating release Day 1 timepoint includes cumulative release over the first day including a separately measured 1 st hour of release, which was ~7 µg for the high - dose and ~4 µg for the low - dose. Values are mean ± SD. Fluctuations during each 2.5 - hour interval are within measurement error 9 Minimal Fluctuations with 2.5 - hour interval sampling Individual Release Profiles (n=6) *Release - rates include exenatide and related substances.

Minimized Implant Size Extendable Implant Duration Tunable Delivery Rate Tunable Delivery Profile NanoPortal TM is a Platform Technology Broad Potential Application Can Support Portfolio of New Drug Implants 10

Targeting the Rapidly Growing GLP - 1 RA Market Vivani Lead Program NPM - 115 High - Dose Exenatide Implant for Chronic Weight Management

• Tremendous unmet medical need in Obesity 1 : • 764M people living with obesity • 15M (2%) taking an anti - obesity medication • GLP - 1 monotherapy may provide adequate weight loss for the majority of patients 2 • Preliminary preclinical data with NPM - 115 has demonstrated similar magnitude of weight loss for exenatide and semaglutide • NPM - 115 target profile may provide an attractive alternative to life - long injections or pills for long - term maintenance of GLP - 1 therapy for weight management 6 - Month Exenatide (Glucagon - like Peptide 1 Receptor Agonist) Implant for Chronic Weight Management in Obese or Overweight Patients Lead Product NPM - 115: 12 1, 2 Novo Nordisk 2023 Annual Report

100% 75% 50% 25% 0% • The remaining opportunity for an additional 60% improvement in persistence is significant and will translate to improved patient outcomes • NPM - 115 (exenatide implant) is designed to guarantee adherence for 6 months / implant Recent retrospective cohort study (n=1,911) reported improved medication persistence with semaglutide of 40% after one year Weight Loss Medicines Associated With Adherence Challenges Large Retrospective Cohort Study* (N=1,911) 13 * Published in Obesity, December 8, 2023 ** NPM - 115 (exenatide implant) was not included in the published study, assumes one implant replaced after six months. Currently under development, designed to enable 100% adherence, not approved in any market. Percent Remaining on Therapy

NPM - 115 is associated with comparable weight loss to semaglutide in preclinical studies 14 Weight loss in high fat diet - induced obese mice. (A) % weight change from baseline for a single administration of NPM - 115 (exenatide, ~530 nmol/kg/day) vs weekly Ozempic injections (semaglutide, 2,700 nmol/kg/week), corrected to control (sham implant) at 28 days; (B) % weight change from baseline over time from a single administration of NPM - 115 (exenatide, ~530 nmol/kg/day) vs. weekly Ozempic injections (semaglutide, 2,700 nmo l/kg/week), corrected to control (sham implant). Values are mean ± SE. A B

Exenatide delivered with NanoPortal™ technology is associated with durable body weight effects 15 Weight difference from control in healthy Sprague - Dawley Rats. % weight change from baseline for a single administration of NPM - 119 (exenatide, ~320 nmol/kg/day) corrected to control (vehicle implant). (A) All animals measured through 105 days of treatment; (B) 5 animals measured in each group through 112 days of treatment followed by a 28 - day recovery period. Values are mean ± SE. A B

NPM - 115 Clinical + Regulatory Development Near - Term Plan November 2023 – Vivani announced the designation of NPM - 115 (high - dose exenatide implant) and initiation of the development program for chronic weight management. February 2024 – Company reported positive preclinical study results demonstrating comparable weight loss between NPM - 115 implant and Ozempic/Wegovy (semaglutide injection). 2024 – Planned submission of an Investigational New Drug Application to support the initiation of a First - in - Human trial of NPM - 115 for the treatment of chronic weight management in obese or overweight patients. 16 Year(s) Milestone Status 2023 Announced Designation of NPM - 115 (high dose exenatide) November 2023 2024 Reported Positive Weight Loss in Preclinical studies February 2024 2024 Submit IND filing to FDA for First - In - Human study Expected 2024

Targeting the Rapidly Growing GLP - 1 RA Market Vivani Lead Program NPM - 119 Exenatide Implant for Type 2 Diabetes

1 2023 Novo Nordisk Annual Report 2 Guo 2016 2,3 Carls et al., 2017 4 IMS 2013 Report • Significant unmet need in Diabetes 1 : • 537M people living with diabetes • ~ 15% in good control • Non - adherence is the primary reason for low, real - world effectiveness 2,3 • Guaranteed adherence will produce significant healthcare cost savings 4 • FDA indicated 505(b)(2) streamlined approval pathway may be available 6 - Month Exenatide (Glucagon - like Peptide 1 Receptor Agonist) Implant for Type 2 Diabetes Lead Product (NPM - 119): 18

NPM - 119 Implant and Applicator 19

Ozempic Januvia Invokana NPM - 119* 100% 75% 50% 25% 0% GLP - 1 agonist, weekly injection Mody et al., 2022 DPP - 4 inhibitors, daily pills Polonsky et al.,2016 SGLT - 2 daily pills Cai et al., 2017 GLP - 1 implant every 6 months • Orals and injectables do not guarantee adherence • Approximately 50% of patients do not meet glycemic targets primarily due to nonadherence NPM - 119* Designed to Enable 100% Adherence through Implant Duration Dual Incentive to Adopt Technology that Improves Adherence • Pharmaceutical revenue is increased • Healthcare costs are decreased Current Drug Adherence Challenge " Drugs don't work in people that don't take them" Real - world Adherence * NPM - 119 – under development, designed to enable 100% adherence, not approved in any market Real - World Adherence of Select Drugs 20

Intarcia’s 1 ITCA 650 (6 - month exenatide implant) may be a relevant value analog for NPM - 119 2014 – Intarcia signed ITCA 650 deal with Servier (excluding US + Japan) $171M up - front, $880M milestones, and double - digit royalties – Financings valued Intarcia as high as $4.0B (2017); Intarcia’s lead program was ITCA 650 2016 – Intarcia filed initial ITCA 650 New Drug Application (NDA) 2017 – FDA issued the first ITCA 650 CRL 2 (cited manufacturing concerns) 2019 – Intarcia re - submitted ITCA 650 NDA 2020 – FDA issued second ITCA 650 CRL (cited clinical safety and device constituent concerns) 2022 – After dispute resolutions, FDA’s CDER proposes to deny Intarcia’s public hearing request 2023 – FDA Advisory Board unanimously recommends against the approvability of ITCA 650 due to concerns about safety risks linked to irregular and uncontrolled exenatide release Value of long - term GLP - 1 (exenatide) implant externally validated previously 1 i2o Therapeutics acquired Intarcia Therapeutic’s assets including ITCA - 650 2 CRL: Complete Response Letter – issued by FDA to identify NDA deficiencies 21

(Intarcia) • FDA alleges that daily variations in drug release may be responsible for clinical safety signals • Larger Device (4mm x 45mm) • Insertion using larger 6 - gauge needle • Minimally fluctuating drug release profile observed in pre - clinical studies • Smaller Device (2.2mm x 21.5mm) • Insertion using smaller 11 - gauge needle NPM - 119 well - positioned to avoid ITCA 650’s device technology challenges NanoPortal TM Osmotic Pump (NPM - 119) 22

Never taken a GLP - 1 RA Patient market research indicates strong market adoption potential for a miniature, 6 - month exenatide implant dQ&A insights reported market research during FDA Advisory Board to review ITCA 650 (exenatide implant) on September 21, 2023 23 56% of patients responded “likely” or “definitely” to get an exenatide implant if FDA approved, prescriber recommended, and covered by insurance

0 2 4 6 8 10 Likely to Prescribe (1=not likely, 10=extremely likely) Primary Care Physicians (n=10) Prescribing Rating, Average 8.3 out of 10 Prescriber and Payer research also provide strong support for a miniature, 6 - month exenatide implant Rating : Overall, using a scale of 1 to 10, where 1 is not at all likely and 10 is extremely likely, how likely are you to prescribe NPM - 119? Vivani sponsored qualitative market research, March 2020. ~90% of patients receive treatment in primary care Total : ~$5,500 (annual, per patient) Adherence = Lower Acute Care & Outpatient Costs Curtis et al., 2017 24

6 - Month NPM - 119 preclinical proof - of - concept achieved Implants removed * 25 Pharmacokinetics of 6 - month NPM - 119 in male Sprague - Dawley rats Exenatide antibody - positive animals are not included in this data set. Values are mean ± SD. *2 of 6 implants are responsible for higher Day 1 exenatide concentrations which is not expected to occur in the configuratio n t o be used in the clinic. ** The estimated exenatide EC50 is 51.4 pg /mL when exenatide antibody titers are < 125 and 84 pg /mL when exenatide antibody titers are >= 125. These exenatide EC50 estimates are consistent with the exenatide EC50 estimate, 83.5 pg /mL, from the FDA Clinical Pharmacology review of BYDUREON **

NPM - 119 Clinical and Regulatory Pathway

Proposed First - in - Human Trial: LIBERATE - 1 Primary Objectives: Safety/tolerability assessment and full PK characterization Glycemic control (HbA1c) and weight will also be assessed Randomize 12 Weeks Key Inclusion/Exclusion Criteria • T2DM and HbA1c <8.5% • On non - exenatide GLP - 1 therapy (discontinued upon enrollment) • May be taking their GLP - 1 in combination with up to 2 of the following: metformin, TZD, SGLT - 2 inhibitor, or DPP - 4 inhibitor • Excluded: SU, insulin T2DM: Type 2 Diabetes Mellitus; TZD: Thiazolidinedione; SGLT - 2: Sodium - glucose cotransporter - 2; DPP - 4: Dipeptidyl peptidase 4; S U: Sulfonylurea 27

NPM - 119 Clinical + Regulatory Development Near - Term Plan July 14, 2023 – Vivani submitted an Investigational New Drug to support a proposed First in Human study also know as LIBERATE - 1 to explore the full pharmacokinetic profile of NPM - 119 in patients with type 2 diabetes. August 18, 2023 – FDA provided a Clinical Hold on the proposed LIBERATE - 1 study primarily due to insufficient Chemistry, Manufacturing and Controls (CMC) information. 2024 - Vivani continues to generate the requested CMC information and remains actively engaged in discussions as part of its efforts to lift the Clinical Hold and enable the expeditious initiation of LIBERATE - 1. Discussions with FDA to resolve the clinical hold are ongoing. Vivani currently expects to submit the requested CMC information to the FDA in the first half of 2024. 28 Year(s) Milestone Status 2023 IND filed to support First - in - Human (LIBERATE - 1) clinical study July 14, 2023 2023 FDA provided Clinical Hold letter August 18, 2023 2024 Generate/Submit New CMC data to Lift Clinical Hold 2024

12 - Week NPM - 119 PK in Rats Intended for explant at 12 weeks in LIBERATE - 1, implants left in place for this study 29 Pharmacokinetics of 3 - month NPM - 119 in male Sprague - Dawley rats Exenatide antibody - positive animals are not included in this data set. Values are mean ± SD. * The estimated exenatide EC50 is 51.4 pg /mL when exenatide antibody titers are < 125 and 84 pg /mL when exenatide antibody titers are >= 125. *

Vivani Medical, Inc. Financial Information

Vivani Medical, Inc. Q4 2023: P&L Statement 31 In Thousands, except per Share Data Dec. 31, 2023 Dec. 31, 2022 Dec. 31, 2023 Dec. 31, 2022 Operating expenses: Research and development, net of grants 4,708$ 4,427$ 16,968$ 14,169$ General and administrative, net of grants 1,509 3,363 9,997 7,072 Total operating expenses 6,217 7,790 26,965 21,241 Loss from operations (6,217) (7,790) (26,965) (21,241) Other income (expense), net 191 506 1,313 7,352 Net loss (6,026)$ (7,284)$ (25,652)$ (13,889)$ Net loss per common share – basic (0.12)$ (0.14)$ (0.50)$ (0.36)$ Net loss per common share – diluted (0.12)$ (0.14)$ (0.50)$ (0.36)$ Weighted average common shares outstanding – basic 51,025 50,736 50,853 38,241 Weighted average common shares outstanding – diluted 51,025 50,736 50,853 38,241 Three Months Ended Twelve Months Ended Condensed Consolidated Statements of Operations (unaudited)

Vivani Medical, Inc. Vivani Medical, Inc. Q4 2023: Balance Sheet 32 In Thousands Dec. 31, 2023 Dec. 31, 2022 ASSETS Cash and cash equivalents 20,654$ 45,076$ Prepaid expenses and other current assets 2,408 2,452 Total current assets 23,062 47,528 Property and equipment, net 1,729 1,182 Right-of-use assets 19,616 779 Restricted cash 1,338 1,366 Deposits and other assets 52 275 Total assets 45,797$ 51,130$ LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities 5,723$ 6,822$ Long-term operating lease liabilities 19,313 — Total liabilities 25,036 6,822 Stockholders’ equity: Total Common Stock, APIC & Other Comp Gain 119,199 117,094 Accumulated deficit (98,438) (72,786) Total liabilities and stockholders’ equity 45,797$ 51,130$ Condensed Consolidated Balance Sheets (unaudited) * Note: In March 2024, Vivani received net proceeds of $13.8M from a registered direct offering of common stock and warrants. *

Vivani Medical, Inc. Q4 2023: Cap Table 33 As of December 31, 2023 Equity WAEP* Number of Shares Common Stock 51,031,097 Stock Options $2.60 6,090,617 RSUs - 402,500 Warrants** $11.60 9,733,068 Fully Diluted Shares 67,257,282 *Weighted Average Exercise Price

Vivani Medical, Inc. 34 Lead programs NPM - 115 and NPM - 119 are miniature, six - month, GLP - 1 (exenatide) implants under development for the treatment of chronic weight management in obese or overweight patients and type 2 diabetes, respectively. NPM - 139 (semaglutide implant) is also under development for chronic weight management with the added potential benefit of once - yearly administration. An innovative, biopharmaceutical company developing a portfolio of miniature, long - term, drug implants to treat chronic disease. Our NanoPortal ™ platform technology enables the design of implants aimed at improving medication non - adherence and tolerability. Vivani is well - positioned to advance NPM - 115 and NPM - 119 towards potentially transformational milestones in 2024.